GET DAILY SIGNALSVeracyte (VCYT) Delivers +15.1% Revenue Growth in Q3 2026 Earnings
Key Takeaways
- Veracyte reported third quarter 2026 total revenue of $151.8 million, up 15.1% year over year and above the consensus estimate of roughly $147.2 million.
- Non-GAAP earnings per share (EPS, or profit divided by shares outstanding) came in at $0.51, beating the consensus estimate of $0.41 by $0.10.
- Testing revenue climbed 15% to $146.4 million, driven by 19% growth in the Afirma test and 12% growth in the Decipher Prostate test.
- Net income reached $31.5 million under generally accepted accounting principles (GAAP), with diluted EPS of $0.38.
- Management updated its full-year 2026 revenue outlook to $590 million to $593 million (14% to 15% growth) and announced a new $100 million share repurchase program.
- For more context on the company, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- To discover AI-driven trading ideas across the market, explore Trending AI Robots.
Why These Results Matter
Veracyte develops molecular tests that support treatment decisions for prostate, thyroid, breast, and bladder cancers. The third-quarter 2026 results offer insight into whether the company can maintain its recent pace of double-digit revenue expansion and improving profitability while funding launches of two new products. After raising guidance twice in the first half, the focus remains on sustained momentum in core tests such as Decipher and Afirma alongside early contributions from newer offerings. Reimbursement trends and adoption rates continue to shape the longer-term margin outlook, and I checked comparable names using Tickeron’s AI Screener to see how Veracyte stacks up within the sector.
Breaking Down the Quarter
For the period ended September 30, 2026, total revenue reached $151.8 million, a 15.1% rise from $131.9 million in the same quarter a year ago and ahead of the $147.2 million consensus estimate. Testing revenue, the primary driver, increased 15% to $146.4 million. Decipher Prostate revenue grew 12% to $92.3 million, while Afirma revenue advanced 19% to $51.5 million.
Non-GAAP EPS of $0.51 surpassed the $0.41 consensus by $0.10. On a GAAP basis, net income totaled $31.5 million with diluted EPS of $0.38, compared with $19.1 million and $0.24 in the prior-year quarter. Full-year 2026 revenue guidance was revised to $590 million–$593 million, implying 14%–15% growth, and the board authorized a $100 million share repurchase program.
Market Reaction and Sentiment
Shares of VCYT have moved sharply around recent earnings releases. The second-quarter report produced a post-earnings decline despite beating estimates, as investors parsed guidance and adoption speed for new tests. This quarter’s revenue and EPS outperformance, paired with the buyback announcement and steady growth outlook, created a more supportive environment. Attention stays on the company’s ability to protect margin gains while commercializing newer products, a dynamic that has produced notable volatility around these updates.
What Investors Should Watch Next
Several areas stand out for continued monitoring. Growth durability in Decipher Prostate and Afirma remains key; Decipher faces guideline-related limits in low-risk settings, making progress in higher- and intermediate-risk prostate cancer worth tracking, while Afirma benefits from workflow gains and lower no-result rates. I’m watching this closely with help from Tickeron’s AI Pattern Search Engine to spot any emerging technical signals.
Commercialization of the Prosigna LDT and TrueMRD test for muscle-invasive bladder cancer is another focal point. Early reimbursement wins and institutional uptake could influence revenue trajectories in upcoming quarters. Profitability trends and capital allocation also merit attention, especially with the new repurchase program underscoring management’s confidence in cash flow and the balance between R&D spending and margin expansion.
Using AI Tools in My Research
When evaluating diagnostic names like this one, I often turn to Tickeron’s AI Screener to quickly filter peers by fundamentals, technical patterns, and performance metrics. It surfaces comparable opportunities in healthcare more efficiently than manual searches and helps confirm whether broader sector trends align with what I see in individual reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VCYT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for VCYT turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 75 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +7.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 205 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for VCYT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VCYT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.041) is normal, around the industry mean (66.911). P/E Ratio (36.472) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Will Having a 529 Plan for My Child Impact His/Her Eligibility For Financial Aid in the Future?
What is Bad Credit?
How Do Embargoes Impact Global Trade and Diplomacy?
Is a Career in Forex Trading Worth Pursuing? Exploring the Pros and Cons
Tickeron Launches Token on Believe App to Engage Crypto Community and Expand Reach
General Information
a company that discovers, develops and commercializes molecular diagnostic solutions
Industry MedicalSpecialties
Advertisement